Investor Relations
Get In Touch
Xilio Therapeutics is a biotechnology company that uses its proprietary technology to develop next-generation cancer immunotherapies.
For investor inquiries: investors@xiliotx.com
For media inquiries: xiliotxmedia@jpa.com
Xilio News
04/12/2021
Xilio Therapeutics Strengthens Management Team with R&D Leadership Appointments
03/29/2021
Xilio Therapeutics Strengthens Leadership Team with the Addition of Two Executives
02/24/2021
Xilio Therapeutics Raises $95 Million in Series C Financing to Advance Potent Tumor-Selective Immuno-Oncology Pipeline
More XILIO News
11/12/2020
Xilio Therapeutics XTX201 (IL-2) Poster Presentation at SITC
11/12/2020
Xilio Therapeutics Presents Promising Preclinical Tumor-Selective Efficacy and Safety Data for XTX201 (IL-2) and XTX101 (anti-CTLA-4) at SITC
11/10/2020
Xilio Therapeutics to Present Data on Tumor-Selective Immunotherapies at the 2020 Society for Immunotherapy of Cancer (SITC) Annual Meeting
11/06/2020
Xilio Therapeutics Appoints Rachel Humphrey, M.D. to Board of Directors
07/23/2020
Xilio Therapeutics Appoints Paul J. Clancy to its Board of Directors
06/17/2020
Xilio Therapeutics Appoints Daniel S. Lynch as Chair of Board of Directors
04/27/2020
Xilio Therapeutics Appoints Martin H. Huber, M.D. as Chief Medical Officer
03/02/2020
Akrevia Therapeutics Rebrands as Xilio Therapeutics and Announces $100.5 Million Series B Financing
06/12/2019
Akrevia Therapeutics Appoints Joseph Farmer as Chief Operating Officer
05/22/2019
Akrevia Therapeutics Appoints ReneĢ Russo, PharmD, as Chief Executive Officer
05/16/2019
Akrevia Therapeutics Appoints Distinguished Research Leaders to Scientific Advisory Board
03/16/2019
Akrevia Therapeutics Licenses Exclusive Rights from City of Hope to Expand Development Pipeline of Potent, Tumor Targeted Immunotherapies
09/27/2018
Akrevia Therapeutics Launches with $30M Series A Financing Led by F-Prime Capital Partners and Atlas Venture